Lugano, Switzerland, 26 September 2023 – The Molecular Analysis for Precision Oncology Congress 2023 (MAP) is the appointment where experts present the latest developments and discuss the present and future of the rapidly evolving field of precision oncology, whose aim is to identify genomic alterations to provide the best possible personalised treatment to patients with cancer. The congress will be held in Paris, France, between 4-6 October.
New this year
-
A special day (6 October, 9:30-15:00 CEST) dedicated to applying precision medicine research to patient care. The so-called RoadMAP to the Clinic 2023 will aim to give visibility to the developments towards molecularly informed, resource-rational and timely advancement of the therapeutic options for patients with cancer. The sessions will deal with the current landscape of research and development and approval of precision therapeutics, with spotlight on the challenge of optimisation, new trial designs and new paths to drug registration; current roadblocks to and future of pan-cancer approvals based on histology agnostic biomarkers.
Programme highlights
-
Multimodal single cell characterization or application of whole-genome sequencing? How to derive a more complete understanding of cancer spatial resolution
Related content: Session on 4 October, 9:30-11:00 CEST -
Evolution-based methods, mathematical modelling, and the tumour microenvironment: improve cancer treatment by understanding the process of clonal evolution and the drivers of cancers
Related content: Session on 4 October, 11:30-13:00 CEST and 14:40-16:10 CEST -
New insights into resistance mechanisms in cancer to advance personalized therapies and improve patient outcomes
Related content: Abstract 5O
Keynote lectures
-
“Role of neutrophils in tumour metastases” by Ilaria Malanchi, 4 October 2023, 14:10-14:40 CEST
-
“Tumour promotion and environmental carcinogens” by Allan Balmain, 5 October 2023, 13:00-13:30 CEST
The results of 169 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press registration
The MAP organisers welcome press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Tuesday, 3 October. Please be kindly informed that onsite press accreditations will not be available.
Further information
MAP Press Office
press@esmo.org
MAP is a joint initiative of Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO).
-END-
Notes to Editors
Please make sure to use the official name of the meeting in your reports: MAP 2023 and the official congress hashtag #MAP2023. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Instagram, Facebook
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 30,000 members representing oncology professionals from 168 countries worldwide, ESMO is the society of reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
About Cancer Research UK (CRUK)
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information. Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 50 years. Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034. Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer. www.cancerresearchuk.org or +44(0) 300 123 1022
About Unicancer
Unicancer is the only French hospital federation 100% dedicated to the fight against cancer, and the only national hospital network exclusively specialised in oncology. It brings together 18 French Comprehensive Cancer Centres (FCCC) and two affiliated members, all non-profit private health care facilities offering a public service, playing a major role in healthcare and research and taking care of nearly 530,000 patients per year. Unicancer is also the leading academic sponsor of clinical trials in oncology, at the European level, with 109 active clinical trials sponsored and approximately 20,000 patients included. The Unicancer network enjoys a worldwide reputation in the field of research, with the production of one third of French publications of international importance in oncology, approximately 700 clinical trials (included or followed up) sponsored in 2022 by the Unicancer network and more than 16% of FCCC’s patients included in clinical trials. Unicancer is also a pioneer in real-world data research, with four national real-world data platforms launched since 2014, involving around fifty healthcare facilities. These platforms have registered over 83,000 patients in the ESME databases across three flagship indications (metastatic breast cancer, ovarian cancer, and lung cancer), and more than 31,000 in the ODH platform, a true observatory for medication and innovation, launched in 2021. Unicancer is also at the forefront of data mobilization at the level of each centre, notably through the Unibase program. www.unicancer.fr/en/